Gemcitabine-treated pancreatic cancer cell medium induces the specific CTL antitumor activity by stimulating the maturation of dendritic cells.

@article{Pei2014GemcitabinetreatedPC,
  title={Gemcitabine-treated pancreatic cancer cell medium induces the specific CTL antitumor activity by stimulating the maturation of dendritic cells.},
  author={Qingshan Pei and Jianmei Pan and Hao Zhu and Xiwei Ding and Wenjia Liu and Ying Lv and Xiaoping Zou and He-sheng Luo},
  journal={International immunopharmacology},
  year={2014},
  volume={19 1},
  pages={10-6}
}
Gemcitabine (GEM) is a first line chemotherapeutic drug for advanced pancreatic cancer. Dendritic cell (DC) vaccine is a promising method of immunotherapy for malignant tumor. Recent research has indicated that gemcitabine can enhance the efficacy of DC vaccine, but precise mechanism is still unknown. Here, we aimed to investigate the effect of GEM on DCs. The results showed that GEM-treated pancreatic cancer cell medium stimulated maturation of DCs. When co-cultured with autologous T… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 36 references

A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2010
View 1 Excerpt

Dendritic cellbased immunotherapy for prostate cancer

JahnischH, S Fussel, +3 authors BachmannM
Clin Dev Immunol • 2010
View 2 Excerpts

Similar Papers

Loading similar papers…